Revisiting risk-adjusted Net Present Value: a practical framework for biotechnology valuation.

Yeon J, Kim C, Kang HS, Bae J, Kim JS

DOI: 10.1016/j.drudis.2026.104717
Published: 2026 Jul
Container: Drug discovery today
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.drudis.2026.104717,
  title = {Revisiting risk-adjusted Net Present Value: a practical framework for biotechnology valuation.},
  author = {Yeon J and Kim C and Kang HS and Bae J and Kim JS},
  year = {2026},
  journal = {Drug discovery today},
  doi = {10.1016/j.drudis.2026.104717},
  url = {https://doi.org/10.1016/j.drudis.2026.104717}
}

RIS

TY  - JOUR
TI  - Revisiting risk-adjusted Net Present Value: a practical framework for biotechnology valuation.
AU  - Yeon J
AU  - Kim C
AU  - Kang HS
AU  - Bae J
AU  - Kim JS
PY  - 2026
JO  - Drug discovery today
DO  - 10.1016/j.drudis.2026.104717
UR  - https://doi.org/10.1016/j.drudis.2026.104717
ER  -

APA

J, Y., C, K., HS, K., J, B., & JS, K. (2026). Revisiting risk-adjusted Net Present Value: a practical framework for biotechnology valuation.. Drug discovery today. https://doi.org/10.1016/j.drudis.2026.104717

Source records

pubmed · retrieved 2026-11-10T12:19:06.666Z
europe-pmc · retrieved 2026-11-10T12:19:06.675Z